Welcome to our dedicated page for Tenax Therapeutics news (Ticker: TENX), a resource for investors and traders seeking the latest updates and insights on Tenax Therapeutics stock.
News for Tenax Therapeutics, Inc. (TENX) centers on its progress as a Phase 3, development-stage pharmaceutical company focused on cardiopulmonary therapies. The company’s updates highlight the clinical and regulatory path of levosimendan, which it is developing for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), a form of pulmonary hypertension for which Tenax states no product has been approved.
Investors following TENX news can expect regular coverage of clinical trial milestones, including enrollment updates, design details, and key analyses from the Phase 3 LEVEL and LEVEL‑2 studies of TNX‑103 (oral levosimendan) in PH-HFpEF. Press releases have described the blinded sample size re-estimation in LEVEL, the initiation of the global LEVEL‑2 study, and the company’s plans for an open-label extension study to provide continued access to TNX‑103 for trial participants.
Tenax news also includes intellectual property developments, such as the European Patent Office’s Intention to Grant a patent covering levosimendan and its active metabolites in PH-HFpEF, and Canadian patent progress for multiple levosimendan formulations and combinations with cardiovascular drugs. These items provide context on the company’s efforts to build long-term protection around its lead asset.
In addition, TENX news features financial results and corporate updates, reported through quarterly earnings press releases, as well as participation in healthcare and investor conferences and virtual KOL events focused on PH-HFpEF and levosimendan. For readers tracking the evolution of Tenax’s late-stage cardiopulmonary program, this news feed offers a consolidated view of trial progress, IP status, and corporate communications. Bookmark this page to follow ongoing disclosures related to TENX and its PH-HFpEF development strategy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Tenax Therapeutics prioritizes the clinical development of TNX-103 (oral levosimendan) for treating pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). This condition affects over 1.6 million North Americans and is expected to exceed 2 million by 2030. The company aims to fill the gap in treatment as there are currently no FDA-approved therapies for PH-HFpEF, with plans to initiate a Phase 3 trial in 2023. The decision to focus on TNX-103 stems from its growing patent estate, potentially providing protection until 2040. A recent patent granted for intravenous levosimendan strengthens its position. Clinical data from the HELP Study supports the drug's efficacy, marking it as a significant advancement in addressing this unmet medical need.
Tenax Therapeutics (Nasdaq: TENX) has secured U.S. Patent No. 11,607,412 for the use of IV levosimendan in treating pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). This patent grants intellectual property protection until December 2040, supporting Tenax's strategy to develop levosimendan, which targets a significant unmet medical need affecting over 1.6 million North Americans. Currently, no FDA-approved treatments exist for PH-HFpEF. Data from the HELP Study indicates that levosimendan significantly improves exercise capacity, further validated by FDA acceptance of the 6-minute walk distance as a Phase 3 endpoint.